TABLE 1.
Group no. | DNA vaccinationa
|
Group PRN50 (individuals)b | Group RIP (individuals)c | ||
---|---|---|---|---|---|
Route | Plasmid | No. | |||
1 | i.d. | pcDNA3-βgal | 2× | − | − |
2 | i.m. | pcDNA3-βgal | 2× | − | − |
3 | g.g. | pcDNA3-βgal | 1× | − | − |
4 | g.g. | pcDNA3-βgal | 2× | − | − |
5 | g.g. | pP12X3C-mut | 1× | − | − |
6 | g.g. | pP12X3C-mut | 2× | − (−, −, −, −, −) | + (+, −, −, −, +) |
7 | i.d. | pP12X3C | 2× | − | − |
8 | i.m. | pP12X3C | 2× | − | − |
9 | g.g. | pP12X3C | 1× | − | − |
10 | g.g. | pP12X3C | 2× | 1.9 (2.5, 2.2, −, −, 1.9) | + (+, +, +, −, +) |
11 | g.g. | piP12X3C | 1× | − (−, −, −d, −e, −) | + (−, +, −, +, −) |
12 | g.g. | piP12X3C | 2× | 2.5 (2.6, −, 2.2, 2.6, 2.5) | + (+, −, +, +, +) |
13 | g.g. | pIRESP12X3C | 1× | − | − |
14 | g.g. | pIRESP12X3C | 2× | − (−, −, −, −, −) | + (+, −, −, +, −) |
15 | g.g. | piIRESP12X3C | 1× | − (−, −, −, −, −f) | + (+, +, −, −, −) |
16 | g.g. | piIRESP12X3C | 2× | 1.9 (2.2, 2.2, −, >2.8, 2.3) | + (+, +, −, +, +) |
17 | g.g. | pIRESLP12X3C | 1× | − | − |
18 | g.g. | pIRESLP12X3C | 2× | − | − |
19 | g.g. | piIRESLP12X3C | 1× | − | − |
20 | g.g. | piIRESLP12X3C | 2× | − | − |
Groups of five mice were inoculated once (1×) or twice (2×) i.d., i.m., or epithelially (g.g.) with the indicated plasmid.
Log of PRN50. Serum samples were tested at a 1:4 starting dilution for pooled samples (1:20 for each individual) and at a 1:20 starting dilution for individual samples. −, no neutralization was detected at the highest concentration tested.
Tested at a 1:4 dilution for pooled samples (1:20 for each individual in pool) and at a 1:20 dilution for individual samples. +, viral proteins visible on autoradiogram; −, no viral proteins visible on autoradiogram.
Starting dilution, 1:200.
Starting dilution, 1:25.
Starting dilution, 1:62.